AU2003234186B2 - Peptide inhibitors of protein kinase C Gamma for pain management - Google Patents

Peptide inhibitors of protein kinase C Gamma for pain management Download PDF

Info

Publication number
AU2003234186B2
AU2003234186B2 AU2003234186A AU2003234186A AU2003234186B2 AU 2003234186 B2 AU2003234186 B2 AU 2003234186B2 AU 2003234186 A AU2003234186 A AU 2003234186A AU 2003234186 A AU2003234186 A AU 2003234186A AU 2003234186 B2 AU2003234186 B2 AU 2003234186B2
Authority
AU
Australia
Prior art keywords
peptide
pain
seq
domain
ypkc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003234186A
Other languages
English (en)
Other versions
AU2003234186A1 (en
Inventor
Joan J. Kendig
Daria Mochly-Rosen
Sarah M. Sweitzer
David C. Yeomans
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of AU2003234186A1 publication Critical patent/AU2003234186A1/en
Application granted granted Critical
Publication of AU2003234186B2 publication Critical patent/AU2003234186B2/en
Priority to AU2009201593A priority Critical patent/AU2009201593B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
AU2003234186A 2002-04-22 2003-04-22 Peptide inhibitors of protein kinase C Gamma for pain management Ceased AU2003234186B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2009201593A AU2009201593B2 (en) 2002-04-22 2009-04-22 Peptide inhibitors of protein kinase C y for pain management

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37453002P 2002-04-22 2002-04-22
US60/374,530 2002-04-22
PCT/US2003/012542 WO2003089457A2 (en) 2002-04-22 2003-04-22 Peptide inhibitors of protein kinase c ϝ for pain management

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2009201593A Division AU2009201593B2 (en) 2002-04-22 2009-04-22 Peptide inhibitors of protein kinase C y for pain management

Publications (2)

Publication Number Publication Date
AU2003234186A1 AU2003234186A1 (en) 2003-11-03
AU2003234186B2 true AU2003234186B2 (en) 2009-01-22

Family

ID=29251202

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2003234186A Ceased AU2003234186B2 (en) 2002-04-22 2003-04-22 Peptide inhibitors of protein kinase C Gamma for pain management
AU2003234185A Ceased AU2003234185C1 (en) 2002-04-22 2003-04-22 Peptide inhibitors of protein kinase C
AU2009201593A Ceased AU2009201593B2 (en) 2002-04-22 2009-04-22 Peptide inhibitors of protein kinase C y for pain management
AU2009201760A Ceased AU2009201760B2 (en) 2002-04-22 2009-05-04 Peptide inhibitors of protein kinase C

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2003234185A Ceased AU2003234185C1 (en) 2002-04-22 2003-04-22 Peptide inhibitors of protein kinase C
AU2009201593A Ceased AU2009201593B2 (en) 2002-04-22 2009-04-22 Peptide inhibitors of protein kinase C y for pain management
AU2009201760A Ceased AU2009201760B2 (en) 2002-04-22 2009-05-04 Peptide inhibitors of protein kinase C

Country Status (6)

Country Link
US (8) US7507711B2 (enExample)
EP (3) EP1501532A4 (enExample)
JP (5) JP2005523326A (enExample)
AU (4) AU2003234186B2 (enExample)
CA (3) CA2481512C (enExample)
WO (2) WO2003089457A2 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005523326A (ja) * 2002-04-22 2005-08-04 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ プロテインキナーゼｃのペプチドインヒビター
US6933275B2 (en) * 2002-05-01 2005-08-23 The Board Of Trustees Of The Leland Stanford Junior University Protein kinase C peptides for use in withdrawal
WO2004084889A1 (en) * 2003-03-28 2004-10-07 Pfizer Inc. Use of protein kinase c inhibitor for suppressing sustained slow postsynaptic excitation (sspe) of enteric neurons
WO2004103266A2 (en) * 2003-05-16 2004-12-02 The Board Of Trustees Of The Leland Stanford Junior University Protein kinase c peptides for use in withdrawal
WO2005032575A1 (en) * 2003-10-02 2005-04-14 The Board Of Trustees Of The Leland Stanford Junior University Protein kinase c peptides for use in withdrawal
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
AU2004297533B2 (en) 2003-10-24 2010-04-29 Gencia Corporation Methods and compositions for delivering polynucleotides
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US8507277B2 (en) * 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US20090208478A1 (en) * 2003-10-24 2009-08-20 Gencia Corporation Transducible polypeptides for modifying metabolism
US20050187156A1 (en) * 2003-12-11 2005-08-25 Daria Mochly-Rosen Isozyme-specific antagonists of protein kinase C
US7265092B2 (en) * 2004-09-30 2007-09-04 Kai Pharmaceuticals, Inc. Pharmaceutical formulation
US20060148700A1 (en) * 2004-11-10 2006-07-06 Daria Mochly-Rosen Methods and compositions for reducing injury to a transplanted organ
US20060160062A1 (en) * 2005-01-14 2006-07-20 Young Lindon H Perfusion and/or preservation solution for organs
US8158586B2 (en) * 2005-04-11 2012-04-17 Pharmagap Inc. Inhibitors of protein kinases and uses thereof
WO2007016763A1 (en) * 2005-08-05 2007-02-15 Pharmagap Inc. Peptides targeted to protein kinase c isoforms and uses thereof
JP5276982B2 (ja) 2005-08-26 2013-08-28 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ オキシトシンの投与による頭痛の処置のための方法
WO2007035782A2 (en) * 2005-09-19 2007-03-29 Kai Pharmaceuticals, Inc. Protein kinase c peptide modulators of angiogenesis
WO2007112556A1 (en) * 2006-03-30 2007-10-11 Salpep Biotechnology Inc. Suppression and treatment of neuropathic pain
US7741290B2 (en) * 2006-06-01 2010-06-22 The Board of Trustee of The Leland Stanford Juinior University Method of preventing progression of hypertension-induced heart failure with PKC peptides
US8067532B2 (en) * 2007-01-19 2011-11-29 Kai Pharmaceuticals, Inc. Modifications of peptide compositions to increase stability and delivery efficiency
US8017583B2 (en) 2007-01-19 2011-09-13 Kai Pharmaceuticals, Inc. Methods of use of epsilon inhibitor compounds for the attenuation of pain
US20090062208A1 (en) * 2007-02-06 2009-03-05 Mochly-Rosen Daria D Methods for maintaining blood-brain barrier integrity in hypertensive subjects using a delta-PKC inhibitor
MX2009010757A (es) * 2007-04-06 2010-02-24 Kai Pharmaceuticals Inc Metodos de uso de compuestos de inhibidor gamma para atenuacion del dolor.
WO2008154004A2 (en) * 2007-06-07 2008-12-18 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of tumor metastases using protein kinase c (pkc) inhibitors
CA2710380A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin 43 poly nucleotide for the treatment of fibrotic conditions
US20090318351A1 (en) * 2008-03-12 2009-12-24 Kevin Grimes Method of treating acute st-elevation myocardial infarction with a delta pkc antagonist
CA2719059C (en) * 2008-03-27 2016-05-17 Nestec S.A. Methods for increasing absorption of peptides, peptidomimetics, and other gastrointestinal transport protein substrates
WO2010019965A1 (en) * 2008-08-15 2010-02-18 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for modulating epsilon protein kinase c-mediated cytoprotection
EP2398897B1 (en) 2009-02-20 2017-06-28 Cellular Dynamics International, Inc. Methods and compositions for the differentiation of stem cells
CA2753679C (en) 2009-02-27 2021-03-02 Cellular Dynamics International, Inc. Differentiation of pluripotent cells
AU2010221168A1 (en) * 2009-03-06 2011-10-06 Angstrom Pharmaceuticals, Inc. Compositions and methods for modulation of cell migration
US20100311671A1 (en) * 2009-03-25 2010-12-09 Kai Pharmaceuticals Transdermal delivery of pkc modulatory peptides through microporated skin
US20120208750A1 (en) 2009-09-29 2012-08-16 Joslin Diabetes Center, Inc. Use of protein kinase c delta (pkcd) inhibitors to treat diabetes, obesity, and hepatic steatosis
CA2795698A1 (en) * 2010-03-05 2011-09-09 Angstrom Pharmaceuticals, Inc. Modulation of intracellular signaling
US8785648B1 (en) 2010-08-10 2014-07-22 The Regents Of The University Of California PKC-epsilon inhibitors
US9217137B2 (en) 2011-08-12 2015-12-22 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for specific regulation of pyruvate dehydrogenase kinase
WO2013163171A1 (en) 2012-04-24 2013-10-31 Kaufman Dan S Method for developing natural killer cells from stem cells
CA2923765C (en) 2013-09-18 2021-06-29 University Of Canberra Stem cell modulation ii
WO2016003450A1 (en) 2014-07-01 2016-01-07 The Regents Of The University Of California Pkc-epsilon inhibitors
AU2015309686B2 (en) 2014-08-25 2020-05-14 Epiaxis Therapeutics Pty Ltd Compositions for modulating cancer stem cells and uses therefor
PL3242676T3 (pl) 2015-01-07 2024-07-15 Tonix Pharma Limited Preparaty oksytocyny zawierające magnez i sposoby ich stosowania
HRP20250215T1 (hr) 2016-04-12 2025-06-20 Tonix Pharma Limited Formulacije oksitocina koje sadrže magnezij i postupci upotrebe
CA3087881A1 (en) 2017-01-17 2018-07-26 Michael David FORREST Therapeutic inhibitors of the reverse mode of atp synthase
CA3099077A1 (en) 2017-07-13 2019-01-17 Michael David FORREST Therapeutic modulators of the reverse mode of atp synthase
CN111587120A (zh) 2017-11-08 2020-08-25 艾比克斯治疗私人有限公司 免疫原性组合物及其用途
EP4078221A1 (en) * 2019-12-16 2022-10-26 Sony Semiconductor Solutions Corporation Time-of-flight imaging circuitry, time-of-flight imaging system, time-of-flight imaging method
TW202146071A (zh) * 2020-03-31 2021-12-16 日商東麗股份有限公司 影像解析裝置、影像解析裝置的控制方法、影像解析系統、及影像解析系統的控制方法
US20250325469A1 (en) 2021-01-24 2025-10-23 Michael David FORREST Inhibitors of atp synthase - cosmetic and therapeutic uses

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4351829A (en) 1980-09-26 1982-09-28 Farmitalia Carlo Erba Spa Use of polypeptides as analgesic drugs
EP0903408A3 (en) 1992-08-21 2005-11-02 Biogen, Inc. Tat-derived transport polypeptide
US5776685A (en) 1993-07-19 1998-07-07 Joslin Diabetes Center Protein kinase C assay
US5935803A (en) 1994-02-01 1999-08-10 Terrapin Technologies, Inc. Methods to identify immunomodulators using cognate interaction of PKC-theta
US5783405A (en) * 1994-02-01 1998-07-21 Terrapin Technologies, Inc. Rapid screening method for effectors of signal transduction
US6165977A (en) 1996-10-18 2000-12-26 Board Of Trustees Of The Leland Stanford Junior University Isozyme-specific activators of protein kinase C methods and compositions
US6376476B1 (en) * 1996-12-13 2002-04-23 Zymogenetics Corporation Isoprenoid pathway inhibitors for stimulating bone growth
US6218113B1 (en) * 1998-02-24 2001-04-17 Incyte Genomics, Inc. Human protein kinase C inhibitor
US6376467B1 (en) * 1998-10-09 2002-04-23 The Regents Of The University Of California Use of inhibitors of protein kinase C epsilon to treat pain
NZ508767A (en) 1998-07-06 2003-12-19 Robert O Use of inhibitors of protein kinase c epsilon to treat pain
EP1100520B1 (en) * 1998-07-21 2004-09-22 Cytovia, Inc. Novel fluorescence dyes and their applications for whole cell fluorescence screening assays for caspases, peptidases, proteases and other enzymes and the use thereof
GB2341389B (en) * 1998-09-14 2000-07-12 Pan Pacific Pharmaceuticals In Useful properties of a bee venom protein and gene encoding same
WO2000018895A1 (en) * 1998-09-25 2000-04-06 The Children's Medical Center Corporation Short peptides which selectively modulate the activity of protein kinases
GB9905218D0 (en) 1999-03-09 1999-04-28 Univ Glasgow Neurodegenerative disorder related gene
JP2003516760A (ja) * 1999-12-02 2003-05-20 ユニヴァーシティー オブ ダンディー プロテインキナーゼ調節
CN1300845A (zh) * 1999-12-22 2001-06-27 上海博德基因开发有限公司 一种新的多肽－人二酰基甘油蛋白激酶亚单位9和编码这种多肽的多核苷酸
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US6496425B1 (en) * 2000-08-21 2002-12-17 Micron Technology, Inc Multiple bit line column redundancy
CA2434643C (en) * 2001-01-18 2013-10-29 The Board Of Trustees Of The Leland Stanford Junior University Peptides for activation and inhibition of.delta.pkc
JP2005523326A (ja) * 2002-04-22 2005-08-04 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ プロテインキナーゼｃのペプチドインヒビター

Also Published As

Publication number Publication date
AU2009201760A1 (en) 2009-05-28
US7507711B2 (en) 2009-03-24
AU2003234185A1 (en) 2003-11-03
WO2003089456A3 (en) 2004-02-12
WO2003089457A3 (en) 2004-01-22
JP2005527209A (ja) 2005-09-15
AU2003234186A1 (en) 2003-11-03
CA2785889A1 (en) 2003-10-30
JP2012176978A (ja) 2012-09-13
US9365837B2 (en) 2016-06-14
AU2009201760B2 (en) 2011-03-17
US7939493B2 (en) 2011-05-10
US7459424B2 (en) 2008-12-02
JP2009102392A (ja) 2009-05-14
WO2003089457B1 (en) 2004-04-15
US20040009922A1 (en) 2004-01-15
US7393835B2 (en) 2008-07-01
US20090143293A1 (en) 2009-06-04
WO2003089457A2 (en) 2003-10-30
AU2003234185C1 (en) 2009-11-19
EP1501533A4 (en) 2007-10-31
EP1501532A2 (en) 2005-02-02
CA2482598C (en) 2012-09-25
CA2481512A1 (en) 2003-10-30
US20030223981A1 (en) 2003-12-04
AU2009201593A1 (en) 2009-05-21
US20090192091A1 (en) 2009-07-30
WO2003089456A2 (en) 2003-10-30
US20140178352A1 (en) 2014-06-26
US8658594B2 (en) 2014-02-25
US20080167247A1 (en) 2008-07-10
AU2009201593B2 (en) 2012-05-24
JP2005523326A (ja) 2005-08-04
JP2009091372A (ja) 2009-04-30
EP1501532A4 (en) 2007-11-14
US7833984B2 (en) 2010-11-16
US20050215483A1 (en) 2005-09-29
CA2482598A1 (en) 2003-10-30
CA2481512C (en) 2013-06-18
EP1501533A2 (en) 2005-02-02
EP2332559A1 (en) 2011-06-15
AU2003234185B2 (en) 2009-02-05
US20110275575A1 (en) 2011-11-10

Similar Documents

Publication Publication Date Title
AU2009201593B2 (en) Peptide inhibitors of protein kinase C y for pain management
Porreca et al. Inhibition of neuropathic pain by selective ablation of brainstem medullary cells expressing the μ-opioid receptor
Qiu et al. Spinal axon regeneration induced by elevation of cyclic AMP
Carter et al. The yellow fluorescent protein (YFP-H) mouse reveals neuroprotection as a novel mechanism underlying chondroitinase ABC-mediated repair after spinal cord injury
Xu et al. Oral application of magnesium-l-threonate attenuates vincristine-induced allodynia and hyperalgesia by normalization of tumor necrosis factor-α/nuclear factor-κB signaling
US20040067886A1 (en) Use of inhibitors of protein kinase C epsilon to treat pain
WO2000001415A2 (en) Use of inhibitors of protein kinase c epsilon to treat pain
Harward et al. BDNF/TrkB signaling and epileptogenesis
AU2012216402A1 (en) Peptide inhibitors of protein kinase Cy for pain management
Iseki et al. Altered expression pattern of testican-1 mRNA after brain injury
AU2011202912A1 (en) Peptide inhibitors of protein kinase C
Sun et al. Protein kinase C substrate activators: potential as novel antidepressants
JP2010090176A (ja) 離脱症状における使用のためのプロテインキナーゼｃペプチド

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired